<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03330470</url>
  </required_header>
  <id_info>
    <org_study_id>15-0253</org_study_id>
    <nct_id>NCT03330470</nct_id>
  </id_info>
  <brief_title>Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease</brief_title>
  <official_title>Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Slovak Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Comenius University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Bratislava</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Slovak Academy of Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the beneficial effects of regular exercise and
      the impact of food supplement carnosine on cognitive, motoric and metabolic functions as well
      as on specific biologically active substances in volunteers with subjective (SCI) or mild
      (MCI) cognitive impairment, as well as in patients in early stages of Parkinson's disease.
      The investigators assume the immediate intervention-associated health benefit for volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard Operating Procedures for patient recruitment, data collection, data management, data
      analysis routinely used in Biomedical Research Center, Slovak Academy of Sciences, University
      Hospital Bratislava and Comenius University, Bratislava will be employed.

      Statistical analysis will be employed to address the primary and secondary objectives, as
      specified in the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glucose tolerance</measure>
    <time_frame>up to 36 months</time_frame>
    <description>changes in glucose tolerance will be determined with oral glucose tolerance test (2h glucose, mmol/l)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>learning/working memory</measure>
    <time_frame>up to 36 months</time_frame>
    <description>exercise related changes in learning/working memory will be determined with the aid of Addenbrook's cognitive test (maximum test score 100)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>motoric functions - Berg Balance Scale</measure>
    <time_frame>up to 36 months</time_frame>
    <description>exercise related changes in motoric functions will be determined with the aid of Berg Balance Scale (maximum score 56)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>habitual physical activity</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Habitual physical activity will be determined with accelerometers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical fitness</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Submaximal aerobic capacity will be determined with one mile walk test</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Subjective Cognitive Impairment</condition>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Parkinson Disease</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>exercise and carnosine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exercise: participants will be subjected to 3 months supervised exercise intervention carnosine supplementation: participants will be instructed to take carnosine 2 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>exercise and supplementation with placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exercise: participants will be subjected to 3 months supervised exercise intervention supplementation with placebo: participants will be instructed to take placebo 2 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stretching controls and carnosine supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stretching controls: participants will be subjected to 3 months supervised stretching program carnosine supplementation: participants will be instructed to take carnosine 2 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stretching controls and supplementation with placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>stretching controls: participants will be subjected to 3 months supervised stretching program supplementation with placebo: participants will be instructed to take placebo 2 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>exercise</intervention_name>
    <description>participants will be subjected to 3 months supervised exercise intervention</description>
    <arm_group_label>exercise and carnosine supplementation</arm_group_label>
    <arm_group_label>exercise and supplementation with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>carnosine supplementation</intervention_name>
    <description>participants will be instructed to take carnosine 2 times daily</description>
    <arm_group_label>exercise and carnosine supplementation</arm_group_label>
    <arm_group_label>stretching controls and carnosine supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>stretching</intervention_name>
    <description>participants will be subjected to 3 months supervised stretching program</description>
    <arm_group_label>stretching controls and carnosine supplementation</arm_group_label>
    <arm_group_label>stretching controls and supplementation with placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>supplementation with placebo</intervention_name>
    <description>participants will be instructed to take placebo 2 times daily</description>
    <arm_group_label>exercise and supplementation with placebo</arm_group_label>
    <arm_group_label>stretching controls and supplementation with placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age 55 - 80 years

          -  Presence of Subjective Cognitive Impairment (SCI), Mild Cognitive Impairment (MCI) or
             early stage of Parkinson's Disease (Hoehn-Yahr 1st-2nd stage), assessed by experienced
             neurologist

        Exclusion Criteria:

          -  Serious systemic cardiovascular, hepatic, renal disease, cancer

          -  Lack of compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Turčáni, Prof., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bratislava, Comenius University, Bratislava,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Valkovič, Prof., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bratislava, Comenius University, Bratislava,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barbara Ukropcová, Assoc. Prof., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Research Center, Slovak Academy of Sciences,</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jozef Ukropec, DrSc, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Research Center, Slovak Academy of Sciences,</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ukropcová, Assoc. Prof., MD, PhD</last_name>
    <phone>+421 2 32295 2261</phone>
    <email>barbara.ukropcova@savba.sk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Bratislava, Comenius University</name>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Biomedical Research Center, Slovak Academy of Sciences</name>
      <address>
        <city>Bratislava</city>
        <zip>84505</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Ukropcová, Assoc. Prof., MD, PhD</last_name>
      <phone>+421 2 32295 2261</phone>
      <email>barbara.ukropcova@savba.sk</email>
    </contact>
    <investigator>
      <last_name>Jozef Ukropec, DrSC., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lucia Slobodová, Mgr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Schon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>October 30, 2017</last_update_submitted>
  <last_update_submitted_qc>October 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Slovak Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Barbara Ukropcová, MD, PhD</investigator_full_name>
    <investigator_title>Assoc. Prof. MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Neurodegenerative Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

